Europe PMC

This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in our privacy notice and cookie policy.

Particular challenges in the use of pulmonary vasodilating therapy for patients with pulmonary hypertension secondary to left heart disease. Letter regarding the article 'Effects of sildenafil on symptoms and exercise capacity for heart failure with reduced ejection fraction and pulmonary hypertension (the SilHF study): a randomized placebo-controlled multicentre trial'.

Author information

Affiliations

  • 1. German Centre for Cardiovascular Research (DZHK), partner site, Berlin, Germany.
      Authors
    • Dandel M 1, 2
    (1 author)
  • 2. Cardio Centrum Berlin, Berlin, Germany.
      Authors
    • Dandel M 1, 2
    • Hetzer R 2
    (2 authors)

European Journal of Heart Failure, 02 Aug 2022, 24(10):1990
https://doi.org/10.1002/ejhf.2622 PMID: 35853842 

A comment on this article appears in "Reply to 'Particular challenges in the use of pulmonary vasodilating therapy for patients with pulmonary hypertension secondary to left heart disease'." Eur J Heart Fail. 2022 Oct;24(10):1990-1992. This is a comment on "Effects of sildenafil on symptoms and exercise capacity for heart failure with reduced ejection fraction and pulmonary hypertension (the SilHF study): a randomized placebo-controlled multicentre trial." Eur J Heart Fail. 2022 Jul;24(7):1239-1248.

Abstract 

No abstract provided.

Full text links 

Read article at publisher's site: https://doi.org/10.1002/ejhf.2622

Citations & impact 

Impact metrics

1
Citation
Jump to Citations

Article citations

Similar Articles 

To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.